Opinion|Videos|July 12, 2024
MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
Dr Garfall, MD, provides further insights around the MajesTEC-1 study.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please provide your key takeaways from this study. How do these updated results impact the potential use of teclistamab in the management of RRMM?
- What is the value of long-term follow-up data in multiple myeloma? How does this impact treatment regimens?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Medicaid MFN Pricing Could Save $8.6 Billion
2
CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks
3
Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia
4
Active US Drug Shortages Rise for Third Straight Quarter
5